AR062917A1 - Nuevo mutante de pestivirus para uso en una vacuna. - Google Patents

Nuevo mutante de pestivirus para uso en una vacuna.

Info

Publication number
AR062917A1
AR062917A1 ARP070104156A ARP070104156A AR062917A1 AR 062917 A1 AR062917 A1 AR 062917A1 AR P070104156 A ARP070104156 A AR P070104156A AR P070104156 A ARP070104156 A AR P070104156A AR 062917 A1 AR062917 A1 AR 062917A1
Authority
AR
Argentina
Prior art keywords
pestivirus
virus
mutants
npro
mutant
Prior art date
Application number
ARP070104156A
Other languages
English (en)
Inventor
Martin Beer
Patricia Koenig
Ilona Reinmann
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR062917A1 publication Critical patent/AR062917A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation
    • C12N2770/24362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente tiene como fin brindar nuevos mutantes de pestivirus para uso en vacunas. Los inventores de la presente trabajaron con mutantes de pestivirus que contenían mutaciones en la region codificadora para la proteína Npro del virus. Los mutantes de acuerdo con la presente se caracterizan porque el mutante se basa en una cepa cp del virus, donde parte de la secuencia génica codificadora de la region Npro es eliminada, y dicha parte eliminada no comprende la secuencia codificadora para los doce aminoácidos N-terminales de la proteína Npro. Preferentemente, el pestivirus es el Virus de la Diarrea Viral Bovina (BVDV). En especial para BVDV, se descubrio que un mutante de acuerdo con la presente es una vacuna candidata segura y eficaz.
ARP070104156A 2006-09-22 2007-09-20 Nuevo mutante de pestivirus para uso en una vacuna. AR062917A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84666206P 2006-09-22 2006-09-22
EP06121147 2006-09-22

Publications (1)

Publication Number Publication Date
AR062917A1 true AR062917A1 (es) 2008-12-17

Family

ID=38658456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104156A AR062917A1 (es) 2006-09-22 2007-09-20 Nuevo mutante de pestivirus para uso en una vacuna.

Country Status (8)

Country Link
US (1) US8071108B2 (es)
EP (1) EP2066342B1 (es)
JP (1) JP5775665B2 (es)
AR (1) AR062917A1 (es)
CA (1) CA2663142C (es)
CL (1) CL2007002704A1 (es)
UY (1) UY30602A1 (es)
WO (1) WO2008034857A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2449013C2 (ru) * 2010-07-05 2012-04-27 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ "ВНИИЗЖ") Штамм "nadl-вниизж" вируса вирусной диареи крупного рогатого скота diarrhea virus bovinum для изготовления биопрепаратов для диагностики, специфической профилактики и лечения вирусной диареи крупного рогатого скота
DK3146042T3 (da) * 2014-05-23 2019-09-30 Boehringer Ingelheim Vetmedica Gmbh Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
CN108456663B (zh) * 2018-03-26 2021-09-21 中国农业科学院兰州兽医研究所 一种1型牛病毒性腹泻病毒样颗粒及其制备与应用
CN114921495A (zh) * 2022-06-15 2022-08-19 中国农业科学院兰州兽医研究所 一种猪瘟病毒病毒样颗粒疫苗的制备方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168942B1 (en) 1998-11-10 2001-01-02 Pfizer Inc. Attenuated forms of bovine viral diarrhea virus
EP1035205A1 (en) 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
US7572455B2 (en) * 2004-05-19 2009-08-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine comprising an attenuated pestivirus
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV

Also Published As

Publication number Publication date
US20090232846A1 (en) 2009-09-17
JP5775665B2 (ja) 2015-09-09
JP2010504084A (ja) 2010-02-12
CA2663142C (en) 2016-05-03
EP2066342B1 (en) 2014-07-23
UY30602A1 (es) 2008-05-02
US8071108B2 (en) 2011-12-06
CA2663142A1 (en) 2008-03-27
CL2007002704A1 (es) 2008-05-30
EP2066342A1 (en) 2009-06-10
WO2008034857A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
ES2525518T3 (es) Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
BRPI0516356A (pt) terapia à base de levedura para infecções crÈnicas da hepatite c
AR062917A1 (es) Nuevo mutante de pestivirus para uso en una vacuna.
AR104448A2 (es) Una composición que comprende un pestivirus atenuado de dvb
AR071220A1 (es) Astrovirus aviario depositado bajo el nuero cncm i-3895
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
ES2562774T3 (es) Vacunas para la gripe basadas en el virus del mosaico de la papaya
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
BRPI0707543B8 (pt) composição de polipeptídeo e uso da mesma
CO6150187A2 (es) Vacunas para malaria
CL2012000091A1 (es) Uso de polipeptidos angtl3 para inducir difereciacion de celulas madres mesenquimales en condrocitos y para preparar un medicamento para mejorar o prevenir artritis o lesiones articulares.
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
TW200641126A (en) N protein mutants of porcine reproductive and respiratory syndrome virus
AR079941A2 (es) Organismos clostridium atenuados recombinados y vacuna
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
CL2008003267A1 (es) Compuestos derivados de macrociclos fusionados con pirrolidina, inhibidores de la serina proteasa ns3; composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la hepatitis c.
NZ631110A (en) Marker vaccine
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
CO2017011964A2 (es) Un metodo para producir hcg recombinante
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
CL2011000742A1 (es) Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion.
AR051853A1 (es) Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
RU2011114984A (ru) Мутантный пестивирус с мутациями в гене core и области ns3

Legal Events

Date Code Title Description
FG Grant, registration